The company has reported a total income of Rs.354.84 crores during the period ended June 30, 2021, as compared to Rs.336.21 crores during the period ended March 31, 2021. The total income for the period ended June 30, 2020, stood at Rs 331.33 crore.

The company has posted net profit / (loss) of Rs.62.6 crores for the period ended June 30, 2021, as against net profit / (loss) of Rs.79.49 crores for the period ended March 31, 2021. The net profit/ (loss), for the period ended June 30, 2020, stood at Rs 49.36 crores.

The company has reported EPS of Rs.1.51 for the period ended June 30, 2021, as compared to Rs.1.93 for the period ended March 31, 2021. The EPS for the period ended June 30, 2020 stood at Rs 1.20.

Commenting on the performance Mr Mark Saldanha, Managing Director, said "We recorded a sales growth of 5.4% led by increased penetration in regulated markets despite pandemic induced logistics issues. We drove gains from operating efficiencies and a debt-free balance sheet resulting in our bottom line increasing by 26.8% in Q1FY22 on Y-o-Y basis.’’

He further added, ``we are delighted to have OrbiMed as a financial partner in our mission to become a global pharmaceutical company. We will continue to invest in our businesses, with Orbimed's global network and resources enabling us to accelerate our growth momentum in the long term."